Loading...
Docoh

13 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2022 Q2
IKNA Ikena Oncology Inc
11 Aug 22
Quarterly report
6:03am
innovation to develop and maintain our proprietary and intellectual property position. The patent position of biotechnology and pharmaceutical companies … the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway
10-Q
2022 Q1
IKNA Ikena Oncology Inc
12 May 22
Quarterly report
6:02am
innovation to develop and maintain our proprietary and intellectual property position. The patent position of biotechnology and pharmaceutical companies … the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biologic products that are biosimilar
DEF 14A
IKNA Ikena Oncology Inc
27 Apr 22
Definitive proxy
4:32pm
2017, most recently as Vice President of Oncology Strategy, Innovation and Collaborations. Prior to joining Pfizer, Dr. Koehler was the group leader … : SPRO). Dr. Formela is a member of the Partners Healthcare Innovation Growth Board and a former trustee of the Boston Institute of Contemporary Art. Dr
10-K
2021 FY
IKNA Ikena Oncology Inc
17 Mar 22
Annual report
6:31am
The biotechnology and pharmaceutical industries are characterized by rapid innovation of new technologies, fierce competition and strong defense of intellectual … and continuing technological innovation to develop and maintain our proprietary and intellectual property position. Our commercial success depends
10-Q
2021 Q3
IKNA Ikena Oncology Inc
10 Nov 21
Quarterly report
6:05am
secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. The patent position … the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biologic products
10-Q
onabg8
12 Aug 21
Quarterly report
4:21pm
10-Q
9s6m92j
13 May 21
Quarterly report
4:15pm
8-K
EX-99.1
fu4euc wj
15 Apr 21
Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors
7:43am
424B4
dazolsw
26 Mar 21
Prospectus supplement with pricing info
5:04pm
S-1/A
gpme9
22 Mar 21
IPO registration (amended)
8:51am
S-1
uje55urj
5 Mar 21
IPO registration
2:59pm
DRS/A
kp2cmxc9v
10 Feb 21
Draft registration statement (amended)
7:00pm
DRS
ll99nodxrui2gb
7 Jan 21
Draft registration statement
7:00pm
  • 1